Febrile neutropenia (FN) is among the most common complications of chemotherapy, and a recent post-marketing, multi-center, real-world, non-interventional, epidemiological study sought to examine the use, safety, and efficacy of biosimilar filgrastim in the primary and secondary prevention of FN.
Febrile neutropenia (FN) is among the most common complications of chemotherapy, and a recent post-marketing, multi-center, real-world, non-interventional, epidemiological study sought to examine the use, safety, and efficacy of biosimilar filgrastim in the primary and secondary prevention of FN.
Secondary prevention of FN is typically offered to a patient who is in a low-risk category for developing FN, but who develops FN during chemotherapy. Primary prevention of FN is offered to high-risk patients with each cycle of chemotherapy. Of the 170 study participants, an overall risk assessment conducted at the first patient visit resulted in the following determinations:
After the risk assessment, 60% of patients received biosimilar filgrastim (Accofil, manufactured by Accord Healthcare, who sponsored the study) as primary prevention of FN, and 40% received biosimilar treatment as secondary prevention. During the second to fifth patient visit (though in 40.6% of patients, 6 cycles of chemotherapy were planned, and in 28.2% of cases, more than 6 cycles were planned), the course of therapy with biosimilar filgrastim was monitored. Data collected, via questionnaire, included the following:
The researchers calculated continuation of therapy with biosimilar filgrastim, average dose of filgrastim, chemotherapy dosage, and FN at each of the 5 visits, and found the following:
An assessment of patient reports found that 70% of patients self-administered the filgrastim injection, and at each visit, over 50% of patients reported “little” soreness caused by the injection. Patient assessments of the convenience of use (on a scale of 1 to 10, where 1 is the least convenient and 10 is the most convenient), showed that approximately 50% of patients rated the convenience of administration as greater than 8.
Assessment of hematological parameters showed that the median neutrophil count identified at visit 1 (2.2×103/µl) did not fall during any of the 5 visits.
The researchers concluded that biosimilar filgrastim was safe, effective, and well tolerated in patients in the primary and secondary prevention of chemotherapy-induced FN, and that administration of the drug was convenient for, and well accepted by, patients.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
What AmerisourceBergen's Report Reveals About Payers, Biosimilar Pricing Trends
May 28th 2023On this episode of Not So Different, Tasmina Hydery and Brian Biehn from AmerisourceBergen discussed results from a recent survey, that were also presented at Asembia 2023, diving into the payer perspective on biosimilars and current pricing trends across the US biosimilar industry.
EHA 2024: Rituximab Biosimilars Improve Quality of Life, Infusion-Related Reactions
June 27th 2024Two posters presented at the European Hematology Association’s annual meeting (EHA 2024) evaluated how rituximab biosimilars impact quality of life and infusion-related reactions in patients with lymphatic cancers.
Biosimilar Adoption in the UK: Patient and Consultant Views on Safety and Switching
June 26th 2024Lack of knowledge and confidence in biosimilars continues despite growing education efforts, impacting provider willingness to prescribe biosimilar medicines and patient perceptions about their treatment and switching to a biosimilar.